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For the detection of tissue alterations progressing to a malignant
tumour, relevant diagnostic instruments and methods are crucial.
This especially is true for detection of early and/or small lesions,
which are not visible macroscopically. Two decades ago, photo-
dynamic diagnosis (PDD) was introduced; its use is increasingly
important in gynaecology (Dougherty and Marcus, 1992). PDD is
based on the administration of a photosensitizer (PS) to cells and
tissues, the subsequent exposure of the tissue to light of specific
wavelength and the detection of a characteristic fluorescence-
emission (Henderson and Dougherty, 1992). This is of clinical
importance since certain PS preferentially accumulate in tumorous
tissue (Kennedy and Pottier, 1994). 
Various substances have been studied including porphyrins,
synthetic porphyrins and phthalocyanins. Modified porphyrins
have systemically been applied for PDD of tumour tissue since the
early 1980s, although the fluorescence signal within the tissue was
not significant, making a clinical use of this method difficult (Kato
et al, 1984). 10 years ago, aminolevulinic acid (ALA) was found
effective for both PDD and photodynamic therapy (PDT)
(Kennedy et al, 1990; Gibson et al, 1997; Peng et al, 1997).
Protoporphyrin IX (PPIX), an endogenously produced porphyrin
and a metabolite of the haem synthesis induced by ALA, accumu-
lates in the mitochondria and can serve as a PS; ferrochelatase is
the rate-limiting step for the incorporation of iron into PPIX. In
some tumours, deaminase-isomerase, the rate-limiting enzyme
that converts porphobilinogen into uroporphyrinogen in the haem
synthesis pathway is increased and ferrochelatase is reduced, so
that PPIX accumulates preferentially in tumour cells (Hua et al,
1995; Heyerdahl et al, 1997; Peng et al, 1997). Photosensitization
by ALA-induced PPIX is tissue specific and is primarily enhanced
in tissues that cover body surfaces, or line body cavities and
exocrine glands such as mammary glands (Kennedy and Pottier,
1994; Marcus et al, 1996; Riesenberg et al, 1996). 
Clinical studies with PDD and PDT using ALA were performed
for the treatment of neural tumours (Obwegeser et al, 1998),
lesions of the oral cavity (Leuing et al, 1996), endoscopical detec-
tion of bronchial lesions (Campbell et al, 1996) and detection of
carcinoma in situ of the bladder during cystoscopy (Kriegmair et al,
1994). The latter reached a sensitivity of 93%. Applications have
been developed for detection of alterations in gynaecological
tissues including the endometrium (Gannon et al, 1995; Steiner et al,
1996), the vulva (Fehr et al, 1996) and skin metastasis of the breast
(Khan et al, 1993). 
Although high levels of PPIX were found in mammary tumour
tissue in vitro (Navone et al, 1990), in mice (Peng et al, 1992) and
in women (Kennedy and Pottier, 1992), no clinical study has been
reported using ALA-PDD for primary mammary tumours. 
In the present report, as a feasibility study, we investigated the
effectiveness of oral application of ALA for PDD in patients with
primary mammary tumours. We monitored the fluorescence inten-
sity (FI) of mammary tissue by fluorescence microscopy and
compared tumorous mammary tissue with normal mammary tissue
and lymph node tissue. We also investigated intraoperative appli-
cation of PDD with ALA for primary mammary tumours. 
PATIENTS, MATERIALS AND METHODS 
The study was performed at the Women’s Hospital Fontana, Chur,
Switzerland. After the approval of the ethical committee in Chur,
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palpable breast tumour with written informed consent were
enrolled in this study. Patients with the following clinical findings
were excluded: porphyria, high levels of liver enzymes, insuffi-
cient function of the liver or the kidney and pregnancy. 
Aminolevulinic acid 
δ -Aminolevulinic acid from ASAT AG, Zug, Switzerland was
used. 16 patients received 40 mg kg–1 bodyweight ALA, which was
freshly dissolved in 50 cl of tap water (pH 2–4) and was applied
3–6 hours prior to surgery.
Protection of patients 
Patients were given Ondansetron (Zofran®) 8 mg together with
ALA. A sun blocker Spirig® (Spiring Pharma AG, Egerkingen,
Switzerland) was applied to face and neck then covered with a
micropigment cream, which has shown good results in light
protection during photosensitization with ALA (unpublished
results). In addition patients were protected from direct light for 24
hours after application of ALA. 
Tumours 
The excised palpable tumours, as well as the lymph nodes, were
protected from light in sealed bottles and transported immediately
to the pathology department, Cantonal Hospital Chur, Switzerland.
Tumours and the lymph nodes were carefully divided into two
parts by a surgical blade and were protected from light. One part
underwent the regular pathological diagnostic procedures. The
other part was stored and frozen in a light protected container at
–80˚C. In a dark chamber 10 cryosections, 10 µ m thick were
prepared from every tumour in the dark. The excised tissue was
cut in a way that there was normal and altered tissue on the same
slide. The sections were wrapped in aluminium foil, sealed in
boxes protecting against drying out and photobleaching, then
stored at –80˚C. These slides were transported on dry ice to the
Research Division of Gynaecology, University Hospital, Zurich.
One section was stained with haematoxylin & eosin for conven-
tional histological information and orientation of unstained sec-
tions. Unstained sections were analysed by fluorescence microscopy.
From every tumour and the corresponding normal tissue, 3
sections were analysed. On every section, 3 pictures (512 pixel2)
of the tumour were compared with the FI of 3 pictures (512 
pixel2) taken from normal mammary tissue. The analysed sections
were additionally stained with haematoxylin & eosin and histolog-
ical information was compared with the digitized FI. 
PDD during surgery 
During a second step, intraoperative PDD was performed. Tumours
were cut into half and then illuminated macroscopically using a
Minolta camera on a stativ (Minolta Dynay 500si with an AF 100
mm objective 1:2.8 (32)) with a diaphragm opening of 5.6. After
tumourectomy, the operation field was illuminated; fluorescence
was detected with a light source (Intralux® mdr100, Volpi AG,
Schlieren, Switzerland). A Xenon lamp 100 W, spectrum 400–780
nm with a liquid light conductor of 15 cm length, an active fibre
diameter of 8 mm and a filter of 430 nm S-10 410 (transmission
band 45%, bandwidth 10 nm) served as a light source. 
Fluorescence microscopy 
Fluorescence imaging was performed with a CCD camera system
(Photometrics, Tucson, AZ, USA) with a Kodak KAF 1600 chip,
coupled to a Leitz DMRB/E fluorescence microscope (Leica,
Glattbrugg, Switzerland). Light from a 50 mW HBO mercury
lamp was filtered through a 405–420 nm broad-bandpass filter to
provide excitation light. A dichroic mirror reflected the excitation
light onto the sample and transmitted the fluorescence emission
through a 635–655 nm broad-bandpass filter onto the detector.
Instrument control, image acquisition, and processing were per-
formed with a Macintosh computer and IPlab® software
(Scanalytics, Fairfax, VA, USA). Tissue images were acquired
with an integration time of 1 s. The FI of the tumour pictures and
normal mammary tissue pictures of every slide were each aver-
aged and the tumour/normal mammary tissue ratio was used for
comparison. FI was expressed as counts per pixel (cpp, arbitrary
units). All optical settings of the microscope were kept constant
for an entire series of image acquisition. 
Statistical analysis 
Comparison of the effectiveness of ALA-based PDD was made
between the group after ALA application and the control, and
between ALA-treated tumours and normal tissue by applying the
nonparametric Mann-Whitney test and Student’s t-test. Stat View®
Software (SAS Institute Inc., Cary, NC, USA) was used for statis-
tical analysis and P < 0.05 was considered to be a statistically
significant difference. 
RESULTS 
Fluorescence microscopy 
Fluorescence intensity of mammary tumours compared with
surrounding normal mammary tissue 
Sections from 13 out of 16 mammary tumours were examined,
after pre-surgical oral application of 40 mg ALA kg–1 bodyweight.
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Figure 1 Fluorescence intensity (FI) of tumour tissue versus normal
surrounding tissue. Columns represent means of data ± SD. Dark columns:
FI of tumour-tissue. White columns: FI of normal surrounding tissue.
(1–13) Tissue of 13 patients after oral intake of 40 mg ALA kg–1 bodyweight.
(A) Auto-fluorescence of a fibroadenoma versus surrounding normal tissue,
(B) Autofluorescence of a carcinoma versus surrounding normal tissue. Two collected tumours did not show any normal tissue and
comparative fluorescence assessment could therefore not be
performed. Tissue of one patient who received ALA was held back
because of change of surgical procedure. The histological report of
the 13 mammary tumours, each from a different patient, revealed
six grade 2 carcinomas (4 cases: ductal invasive carcinoma, 2
cases: lobular carcinoma), one grade 1 carcinoma (mucinous carci-
noma) and six fibroadenomas. Every tumour showed a highly
significant difference in fluorescence intensity compared to the
surrounding normal mammary tissue (Table 1). FI from tumour
tissue was 2.2–5.2 fold higher than normal mammary tissue. FI of
tumour tissue ranged from 35.1–75.4, normal mammary tissue
ranged from 10.1–25.5. We generated a ratio between the tumours
and the normal surrounding mammary tissue in order to compare
the tumours with each other. We have chosen this approach
because the absolute intensity of fluorescence varied from patient
to patient. The mean ratio ± SD was 3.59 ± 1.09. No significantly
different ratio was found between benign and malignant tumours.
Autofluorescence of the tumour tissue, considered as the back-
ground fluorescence of the tissue, without additional exposure to
ALA was measured in one patient with fibroadenoma and in one
with carcinoma. There was no increased FI measured in tissue of
controls (Figures 1, 2). 
Fluorescence intensity of axillary lymph nodes after
application of ALA 
We examined 8 lymph nodes from 3 patients who had axillary
lymphonodectomy after tumourectomy of the breast during the
same surgical session. The macroscopic appearance of the lymph
nodes was normal. The histological report on all the lymph nodes
was negative for malignancy. We hypothesized that in order to see
tumour metastasis fluorescing in the lymph node, the lymph nodes
tissue itself must have a lower fluorescence than the tumour tissue.
The mean ±SD FI of the lymph node tissue was as follows: photo-
sensitized lymph nodes: 50.57 ± 35.8, autofluorescence of lymph
nodes 14.53 ± 3.7. The difference was highly significant (P =
0.0002). The mean ±SD of FI in patient A (28.4 ± 17.1) was
considerably lower than in patient B (61.7 ± 30.8) and patient C
(45.9 ± 25.2). However, when comparing FI of the nonmetastatic
lymph node tissue with FI of the primary breast tumour of the
same patient, only patient A revealed significantly higher FI in the
mammary tumour tissue than in the lymph node tissue (P < 0.001).
Patients B and C showed no significant difference (B: P = 0.44, C:
P = 0.55). 
Comparison of fluorescence intensity of tumours with time
between ALA application and tumour excision 
Tumours were excised between 150–420 minutes after oral appli-
cation of 40 mg ALA kg–1 bodyweight. 11 out of 13 tumours
(85%) were excised within 180–320 minutes post photosensitiza-
tion. There was no correlation between excision latency and FI or
ratio of FI (Table 1). 
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Figure 2 Fluorescence microscopy (20  ) of tumour versus normal
mammary tissue after oral photosensitization with ALA (B, D) with
corresponding pictures after staining with haematoxylin & eosin (A, C). (B)
Fluorescence picture of fibroadenoma, (D) Fluorescence picture of normal
mammary tissue. 
Table 1 List of patients 
Patientsa Tumourb Normal tissuec Ratiod t-teste FA/CAe Timef
1 50.62 ± 14.2 17.0 ± 4.49 3.0 0.0010 FA 420 
2 88.64 ± 24.88 17.03 ± 4.2 5.2 0.0001 CA 205 
3 44.13 ± 19.42 14.73 ± 4.06 3.0 0.0002 CA 150 
4 48.92 ± 14.52 22.51 ± 6.92 2.2 0.0024 FA 230 
5 72.19 ± 32.84 15.87 ± 4.26 4.6 0.0008 CA 180 
6 44.54 ± 23.57 13.14 ± 2.41 3.4 0.0120 FA 250 
7 61.08 ± 48.31 12.33 ± 2.12 5.0 0.0004 FA 310 
8 74.8 ± 29.25 20.38 ± 3.42 3.7 0.0039 FA 200 
9 53.26 ± 26.49 25.45 ± 7.75 2.1 0.0112 CA 240 
10 42.88 ± 30.38 10.06 ± 1.04 4.3 0.0002 FA 240 
11 35.09 ± 9.79 16.42 ± 2.88 2.1 0.0002 CA 270 
12 52.73 ± 18.77 15.32 ± 1.88 3.4 0.0004 CA 230 
13 75.4 ± 45.1 16.08 ± 3.6 4.7 0.0014 CA 310 
A 11.68 ± 2.0 12.76 ± 1.45 0.9 0.2080 FA 0 
B 11.43 ± 1.7 17.3 ± 3.54 0.7 0.0010 CA 0 
aPatients 1–13 were photosensitized prior to surgery with 40 mg ALA kg–1 bodyweight. Patients A and B served as controls: no application of ALA. bMean of FI ±
SD of benign or malignant tumour tissue. cMean of FI ±  SD of surrounding normal mammary tissue. dRatio of means of FI tumour tissue/normal mammary
tissue. eStudent’s t-test: Difference between FI of tumour tissue versus normal surrounding mammary tissue. eFA: fibroadenoma, CA: carcinoma. fTime interval
between oral intake of ALA and tumourectomy. Intraoperative fluorescence of tumours 
Whole mount fluorescence in tumours 
Tumours were excised, cut into half and exposed to blue light.
Intense red fluorescence was shown (Figure 3). Intraoperatively,
tumours could also be detected and described after darkening the
room and exposure to blue light (not recorded). 
Side effects from oral application of ALA 
Oral application of ALA at a concentration of 40 mg kg–1 body-
weight had little and short-lived side effects. Prior to this study 5
patients (unpublished data) who were photosensitized with 60 mg
ALA kg–1 bodyweight developed the following side effects: 3
patients developed a facial erythema in the evening and oedema of
the eyelids. They had paranasal swelling with an itchy feeling but
recovered completely within 72 hours. One patient had severe
nausea 2 hours after intake of ALA and 2 patients had postopera-
tive nausea. Due to these side effects the concentration of ALA
was reduced to 40 mg kg-1 bodyweight for this study. With this
concentration applied to 16 patients, 2 patients developed a facial
erythema in the evening, but without itching. Perinasal swelling
was a common finding which affected 75% of the patients without
subjective distress. All of them recovered within 72 hours
completely. There was one patient with severe sunburn that
lingered for 5 days resulting from a combination with homeo-
pathic medication (Hypericin extract). The patient had not
mentioned the medication prior to surgery. This substance is
known for its photosensitizing side effects and we could prove
synergistic effect with ALA in vitro (unpublished data). 
DISCUSSION 
All mammary tumour samples examined by fluorescence
microscopy presented a significantly higher fluorescence intensity
than the normal surrounding tissue. Autofluorescence was very
low and similar in both normal and tumour tissue of the breast.
This corresponds to earlier findings in mice (Peng et al, 1992). In
addition, intraoperative fluorescence of tumour tissue after initial
operative exposure before and after removal emphasizes the poten-
tial of this new tool to discriminate primary mammary tumours
from normal tissue intraoperatively. Further characterization of the
tumour tissue will rely on the pathologist, since FI between benign
and malignant tumours did not show any significant difference.
We believe that this method will be of help to determine the extent
of tumour involvement and therefore give the surgeon real-time
information on whether a sufficient margin has been allowed,
resulting in an increased radicality in breast tumour management.
This has been proposed previously for mammary tumours after i.v.
application of Photofrin (Svanberg et al, 1998). The qualities of
ALA however, make a clinical application for PDD more feasible. 
Kriegmair et al have used this procedure to detect carcinoma in
situ of the human bladder (Kriegmair et al, 1994). The present
study only evaluated women with palpable tumours. Because of
the presence of a significant difference in fluorescence intensity of
altered and normal mammary tissue, we believe that this method
may well have the potential to detect small breast tumours or
carcinoma in situ. It will therefore be interesting to further pursue
this issue with regards to nonpalpable tumours and eventually
carcinoma in situ. Furthermore, we consider a combination of
PDD with PDT as a possible approach to combine diagnosis with
treatment. PS of the most recent generation have their spectrum of
absorption at higher wavelength (650–740 nm) enabling deeper
penetration into the tissue and thus enhancing the therapeutic
effect of the procedure. 
We found a large variation in FI among our patients. This is in
accord with the literature stating that many factors influence the
amount of PPIX accumulated in the tissue. For example, FI
increases exponentially over the pH range between 6 and 8
(Krammer and Uberriegler 1996). In addition, metabolism of ALA
varies from one patient to another. We therefore have chosen a
specific ratio of FI in the tumour and in the surrounding tissue
enabling a comparison between all patients. 
Various ways of ALA administration have been studied. Topical
administration was very efficient and did not show relevant side
effects. Targeting the PS to the tumour, especially when it is not
located on the surface, however, is a problem for topical applica-
tion. This can be overcome by endogenous photosensitization with
oral or intravenous administration of ALA. It was shown that oral
ALA administration takes more time than intravenous application
to induce PPIX fluorescence in the various tissues, but shows
fewer side effects (Van den Boogert et al, 1985; Loh et al, 1993).
Oral application of ALA is thus accompanied by systemic photo-
sensitization, but in contrast to other porphyrins, which stay within
the body for many days or weeks, photosensitization by ALA is
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Figure 3 Photosensitized (A) and nonphotosensitized (B, C) fibroadenoma cut into half. The surface of the photosensitized tumour shows intense
fluorescence during exposure to blue light (A). Nonphotosensitized fibroadenoma (B, C) is barely visible during exposure to blue light (B) compared to exposure
with white light (C). limited to 24 hours after intake. Dose related side effects have been
examined with the conclusion that doses of 60 mg kg–1 bodyweight
are acceptable but more likely to produce side effects such as
nausea and phototoxic reaction of the light exposed skin, than 40
mg kg–1 (Webber et al, 1997). On the other hand, the higher dose is
expected to produce a higher FI. The chosen dosage of 40 mg kg–1
bodyweight was convenient to the patients in almost all cases.
However, paranasal oedema was a common finding that had not
been reported before. Such side effects after oral intake of ALA
will need to be studied in greater detail. 
As for lymphatic tissue, it has been shown that PPIX accumu-
lates preferentially in active lymphatic tissue (Eleouet et al, 1997)
such as lymphomas. Nonmetastatic lymph nodes in 2 out of 3
patients showed high FI. In fact, the FI of the nonmetastatic lymph
node tissue was as high as the FI in the primary mammary tumours
of the same patient. We therefore assume that metastasis of the
breast tumour could not be detected in the lymph nodes by our
means, although the number of lymph nodes examined does not
allow a final conclusion. 
Based on this feasibility study, we suggest that PDD with ALA
for breast tumours should be further investigated and developed
for intraoperative use and may be a simple tool for intraoperative
diagnosis and safe recognition of tumour margins. 
ACKNOWLEDGEMENTS 
The authors acknowledge A Kurmanaviciene for fluorescence
microscopy, A Mueller, ETH Zurich, Switzerland, for statistical
advice, C Heinz, Cantonal Hospital Chur, Switzerland, Department
of Pathology for histological preparations and F Schleiss, P Fehr, I
Strnad, Woman’s Hospital Fontana, Chur, Switzerland, for partici-
pation and support in clinical trial. 
This study was supported by a grant from the Swiss Med Tech
Initiative programme, dedicated to the improvement of ALA
substances (Grant No 551,3804), by ASAT AG, Zug and by Volpi
AG. Schlieren, Switzerland.
REFERENCES 
Campbell DL, Gudgin-Dickson EF, Forkert PG et al (1996) Detection of early stages
of carcinogenesis in adenoma of murin lung by 5-aminolevulinic acid-induced
protoporphyrin IX fluorescence. Photochem Photobiol 64(4): 676–682 
Dougherty TJ and Marcus SL (1992) Photodynamic therapy. Eur J Cancer 28A (10):
1734–1742 
Eleouet S, Carre J, Vonarx V et al (1997) Delta-aminolevulinic acid-induced
fluorescence in normal human lymphocytes. J Photochem Photobiol B 41: 22–29 
Fehr MK, Chapman CF, Krasieva T et al (1996) Selective photosensitizer
distribution in vulvar condyloma acuminatum after topical application of 5-
aminolevulinic acid. Am J Obstet Gynecol 174(3): 951–957 
Gannon MJ, Johnson N, Roberts DJH et al (1995) Photosensitization of the endometrium
with topical 5-aminolevulinic acid. Am J Obstet Gynecol 173(6): 1826–1828 
Gibson SL, Havens JJ, Foster TH and Hilf R (1997) Time-dependent intracellular
accumulation of delta-aminolevulinic acid, induction of porphyrin synthesis
and subsequent phototoxity. Photochem Photobiol 65(3): 416–421 
Henderson BW and Dougherty TJ (1992) How does photodynamic therapy work?
Review. Photochem Photobiol 55: 145–157 
Heyerdahl H, Wang I, Liu DL et al (1997) Pharmacokinetics studies on 
5-aminolevulinic acid-induced protoprophyrin IX accumulation in tumors and
normal tissue. Canc Lett 112: 225–231 
Hua Z, Gibson SL, Foster TH and Hilf R (1995) Effectiveness of delta-
aminolevulinic acid-induced protoporphyrin as a photosensitizer for
photodynamic therapy in vivo. Cancer Research 55: 1723–1731 
Kato H, Okunaka T and Shimatani H (1984). Clinical measurement of tumor
fluorescence using a new diagnostic system with hematoporphyrin derivative,
laser photoradiation, and a spectroscope. Lasers Surg Med 4(1): 49–58 
Kennedy JC and Pottier RH (1992) Endogenous protoporphyrin IX, a clinically
useful photosensitizer for photodynamic therapy. J Photochem Phtobiol B 14:
275–292 
Kennedy JC and Pottier RH (1994) Using delta-aminolevulinc acid in cancer
therapy. Porphyric pesticides, Chapter 21 
Kennedy JC. Pottier RH and Pross DC (1990) Photodynamic therapy with
endogenous protoporphyrin IX: basic principles and present clinical
experience. J Photochem Photobiol B 6(1–2): 143–148 
Khan SA, Dougherty TJ and Mang TS (1993) An evaluation of photodynamic
therapy in the management of cutaneous metastases of breast cancer. Eur J
Cancer 29A(12): 1686–1690 
Krammer B, Uberriegler K (1996) In-vitro investigation of ALA-induced
protoporphyrin IX. J Photochem Photobiol B 36: 121–126 
Kriegmair M, Baumgartner R, Knuechel R et al (1994) Fluorescence photodetection
of neoplastic urothelial lesions following intravesical instillation of
5-aminolevulinic acid. Urology 44(6): 836–41 
Leuing A, Rick K, Stepp H et al (1996) Fluorescence imaging and spectroscopy of
5-aminolevulinic acid induced protoporphrin IX for the detection of neoplastic
lesions in the oral cavity. Am J Surg 172: 674–677 
Loh CS, MacRobert AJ, Bedwell J et al (1993) Oral versus intravenous
administration of 5-aminolaevulinic acid for photodynamic therapy. Br J
Cancer 68(1): 41–51 
Marcus SL, Sobel RS, Golub AL et al (1996) Photodynamic therapy (PDT) and
photodiagnosis (PD) using endogenous photosensitization induced by 5-
aminolevulinic acid (ALA): current clinical and development status. J Clin
Laser Med Surg 14(2): 59–66 
Navone NM, Polo CF, Frisardi AL, et al (1990) Heme biosynthesis in human breast
cancer-mimetic “in vitro” studies and some heme enzymic acitivty levels. Int J
Biochem 22(12): 1407–1411 
Obwegeser A, Jakober R and Kostron H (1998) Uptake and kinetics of 14C-labelled
meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat
glioma model. Br J Cancer 78(6): 733–738 
Peng Q, Moan J, Warloe T et al (1992) Distribution and photosensitizing efficiency
of porphyrins induced by application of exogenous 5-aminolevulinic acid in
mice bearing mammary carcinoma. Int J Cancer 52(3): 433–443 
Peng Q, Warloe T, Berg K et al (1997) 5-Aminolevulinic acid-based photodynamic
therapy. Cancer 79(12): 2282–2308 
Riesenberg R, Fuchs C and Kriegmair M (1996) Photodynamic effects of
5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells
in vitro. Eur J Cancer 32A(2): 328–334 
Steiner RA, Tadir Y, Tromberg BJ et al (1996) Photosensitization of the rat
endometrium following 5-aminolevulinic acid induced photodynamic therapy.
Lasers Surg Med 18(3): 301–308 
Svanberg K, Wang I, Colleen S et al (1998) Clinical multi-colour fluorescence
imaging of malignant tumours – initial experience. Acta Radiol 39: 2–9 
Van den Boogert J, Van Hillegersberg R, De Rooij FW et al (1985)
5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues:
pharmacokinetics after oral or intravenous administration. J Photochem
Photobiol B 44(1): 29–38 
Webber J, Kessel D and Fromm D (1997) Side effects and photosensitization of
human tissues after aminolevulinic acid. J Surg Res 68(1): 31–37 
PDD of breast tumours after oral intake of ALA 37
British Journal of Cancer (2001) 84(1), 33–37 © 2001 Cancer Research Campaign